Holen Sie sich die Stockscreener-App
0.5501
1.49%
0.0081
Schlusskurs vom Vortag:
$0.542
Offen:
$0.5711
24-Stunden-Volumen:
67,291
Relative Volume:
0.21
Marktkapitalisierung:
$8.45M
Einnahmen:
$2.73M
Nettoeinkommen (Verlust:
$-19.43M
KGV:
-0.2419
EPS:
-2.2739
Netto-Cashflow:
$-17.91M
1W Leistung:
-6.75%
1M Leistung:
-0.58%
6M Leistung:
-67.26%
1J Leistung:
-66.96%
1-Tages-Spanne:
$0.5401
$0.5711
1-Wochen-Bereich:
$0.5401
$0.61
52-Wochen-Spanne:
$0.4301
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Firmenname
Traws Pharma Inc
Sektor
Branche
Telefon
267-759-3680
Adresse
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
0.5501 | 7.99M | 2.73M | -19.43M | -17.91M | -2.2739 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-18 | Eingeleitet | Guggenheim | Buy |
| 2018-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-27 | Eingeleitet | Laidlaw | Buy |
| 2015-07-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten
Traws Pharma prepares MHRA resubmission for influenza study - scanx.trade
H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Traws Pharma Ties Up To $50 Million Of Additional Financing To Influenza Regulatory And Clinical Milestones - Pulse 2.0
TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00 - GuruFocus
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 - Investing.com
Traws Pharma shares rise after Q2 loss comes in better than expected - Yahoo Finance
Traws Pharma beats Q2 loss estimates, shares jump 4% By Investing.com - Investing.com South Africa
Traws Pharma beats Q2 loss estimates, shares jump 4% - Investing.com
TRAW Looks 95.6% Undervalued on GF Value™ Amid Price-to-Sales Co - GuruFocus
Traws Pharma Inc (TRAW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Did TRAW Stock Slump 28% After Hours? - Stocktwits
Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma - Stock Titan
Traws Pharma Flags Cash Runway Risk Into Q1 2027 Amid FDA Clinical Hold - Minichart
Traws Pharma Reports Q2 Results, Influenza Program Advances - TipRanks
Traws Pharma Q2 Results: EPS beats estimate, losses widen 45% YoY - scanx.trade
Traws Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Traws Pharma, Inc. Q2 2026: Revenue $0 EPS $(0.16) — 10-Q Summary - TradingView
TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high - TradingView
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens - TradingView
Traws Pharma Reports Q2 2026 Net Loss of $3.0 Million - Quiver Quantitative
Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A - Stock Titan
Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership - Stock Titan
Traws Pharma Inc (NASDAQ: TRAW) Share Price, TRAW Stock News, TRAW Share Price & Updates - Kalkine
Adage Capital reports 4.79% Traws Pharma (TRAW) stake totaling 730,000 shares - Stock Titan
Traws Pharma Q1 2026 Earnings: Net Loss Narrows Sharply, EPS Beats Consensus by 29.78%Annual Report - vinanet.vn
Traws Pharma Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Traws Pharma Inc (TRAW) Stock News Today - TradingKey
TRAW Q1 2026 Earnings: Loss Narrows 29.8% Versus Estimates as Pre-Revenue Biotech Holds CourseEPS Consistency Score - vinanet.vn
TRAW Q2'26 Earnings: EPS estimate is (0.34) USD - TradingView
TRAW Moves TRX-100 Through Early Human Testing: What Investors Should Watch - tipranks.com
Traws Pharma Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Traws Pharma, Inc. Revenue Breakdown – NASDAQ:TRAW - TradingView
Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentROIC Trend Report - dars.gov.et
Traws Pharma Received Notice of Noncompliance - TradingView
TRAW Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Traws Pharma Inc (TRAW) Balance Sheet - TradingKey
TRAW|Traws Pharma Inc|Price:0.520|Chg%:+0.032 - TradingKey
Traws Pharma Inc (TRAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Traws Pharma Inc (TRAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TRAW|Traws Pharma Inc|Price:0.546|Chg%:+0.006 - TradingKey
TRAW|Traws Pharma Inc|Price:0.488| - TradingKey
Traws Pharma, Inc. Revenue Breakdown – LS:A40PJ7 - TradingView
Traws Pharma Inc (TRAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Traws Pharma Inc (TRAW) Income Statement - TradingKey
Traws Pharma Inc (TRAW) Cash Flow - TradingKey
Traws Pharma Inc (TRAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Traws Pharma (TRAW) Slides 10.6% as Selling Pressure IntensifiesRetail Sentiment - dars.gov.et
Traws Pharma (TRAW) Registration filing Summary - Quartr
Finanzdaten der Traws Pharma Inc-Aktie (TRAW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):